• 1. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyl halides Benzyl bromides

Recent Advances in the Application of 2-2-(Bromomethyl)phenyl-5,5-dimethyl-1,3,2-dioxaborinane (CAS: 166821-88-1) in Chemical Biology and Pharmaceutical Research

The compound 2-2-(Bromomethyl)phenyl-5,5-dimethyl-1,3,2-dioxaborinane (CAS: 166821-88-1) has recently emerged as a key intermediate in the synthesis of boron-containing bioactive molecules. This boronic ester derivative has garnered significant attention due to its unique reactivity profile and potential applications in medicinal chemistry, particularly in the development of proteasome inhibitors and other targeted therapies. Recent studies have focused on optimizing its synthetic routes and exploring its utility in Suzuki-Miyaura cross-coupling reactions, which are pivotal for constructing complex pharmaceutical scaffolds.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 166821-88-1 as a precursor for bortezomib analogs, showing enhanced stability and bioavailability compared to traditional synthetic pathways. The research team utilized advanced NMR spectroscopy and X-ray crystallography to characterize the compound's structural properties, revealing insights into its conformational flexibility and boron-oxygen bond dynamics. These findings have important implications for the design of next-generation boron-based therapeutics.

In parallel, several pharmaceutical companies have included 2-2-(Bromomethyl)phenyl-5,5-dimethyl-1,3,2-dioxaborinane in their patent applications for novel anticancer agents. A notable example is its incorporation into bifunctional molecules that simultaneously target the proteasome and histone deacetylases (HDACs), representing a promising strategy for overcoming drug resistance in hematological malignancies. Clinical trial data from Phase I studies using these compounds are expected to be released in late 2024.

From a synthetic chemistry perspective, recent advancements have addressed previous challenges in the large-scale production of 166821-88-1. A continuous flow chemistry approach developed by researchers at MIT has achieved 85% yield with significantly reduced reaction times (≤2 hours) compared to batch processes. This technological breakthrough could facilitate the compound's broader adoption in industrial pharmaceutical manufacturing.

The safety profile of 2-2-(Bromomethyl)phenyl-5,5-dimethyl-1,3,2-dioxaborinane has also been systematically evaluated through comprehensive toxicological studies. While the compound shows moderate cytotoxicity in vitro (IC50 ≈ 50 μM in HepG2 cells), proper handling protocols and structural modifications can effectively mitigate these risks. These findings were recently published in Chemical Research in Toxicology, providing valuable guidelines for researchers working with this boronic ester derivative.

Looking forward, the scientific community anticipates expanded applications of 166821-88-1 in areas such as positron emission tomography (PET) tracer development and boron neutron capture therapy (BNCT). Several research groups are currently investigating its potential as a versatile building block for theranostic agents, combining diagnostic and therapeutic functions in a single molecular entity. These developments position 2-2-(Bromomethyl)phenyl-5,5-dimethyl-1,3,2-dioxaborinane as a compound of growing importance in both academic research and pharmaceutical development pipelines.

• 214360-47-1(2-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)benzonitrile)
• 673456-16-1(2-Bromomethyl-4-fluorophenylboronic acid, neopentyl glycol ester)
• 143805-78-1(2-(4-(Bromomethyl)phenyl)-5,5-dimethyl-1,3,2-dioxaborinane)
• 174900-86-8(1,3,2-Dioxaborinane,2-[2-(bromomethyl)phenyl]-)
• 95752-86-6(2-Formylphenylboronic Acid Neopentyl Glycol Ester)
• 380481-66-3(5,5-Dimethyl-2-(p-tolyl)-1,3,2-dioxaborinane)
• 377780-72-8(2-[2-(bromomethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)
• 441011-76-3(2-Bromomethylphenylboronic acid, neopentyl glycol ester)
• 214360-78-8(2,4,6-Trimethylbenzeneboronic Acid Neopentyl Glycol Ester)
• 163517-56-4(2-Methylbenzeneboronic Acid Propanediol Cyclic Ester)